Oct. 25 at 1:26 AM
$VKTX the issue If BP understand phase 2 data and extrapolate to approval after all the dump predictions by novo and some analysts on CagriSema , MariTide , orforglipron….that were wrong. Probably as phase 3 trials progress and efficacy , safety leak .. more confidence grows.
CEOs such as Bourla were more comfortable taking risk on a few billions. Here we talk about much more. Also Trump Lilly deal should settle uncertainty.